Treats recurrent herpes labialis (cold sores). Sold as Xerese. Every FDA application for this active ingredient.
As of Nov 13, 2026, FDA lists 1 application for Acyclovir; Hydrocortisone (sold as Xerese), first approved Jul 31, 2009, with 1 new use approved and 0 published complete response letters.
| Product | Part | Spending, 2025 | Change | Beneficiaries |
|---|---|---|---|---|
| Xerese | Part D | $427K | -26% | 220 |
| A Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Study to Evaluate the Safety and Efficacy of Uterine Blood Mesenchymal Stem Cells Injection for the Treatment of Severe Pneumonia Caused by VirusesSevere Viral Pneumonia(Not Include COVID-19) · Ruijin Hospital | Phase 1 | Recruiting | Nov 18, 2024 |
| Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)Coronavirus Infection (COVID-19), Pulmonary Arterial Hypertension · Duke University | — | Recruiting | Feb 20, 2020 |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA
